Lecture 3 Dr.Narmin Hussen

Slides:



Advertisements
Similar presentations
Pharmacological Management of Parkinson’s Disease
Advertisements

Parkinsons Disease Management in Primary Care. Introduction Progressive condition 1:500 whole population 1:50 of elderly 1:10 Nursing Home Residents.
Parkinson Disease (PD) Treatment Update. Outlines The Basics: – PD Introduction and motor symptoms. – DDx not to miss. – Different classes of Anti PD.
Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
Diagnosis and Management of Parkinson’s Disease
ILOs At the end of this lecture you will be able to:- Recognize the symptoms and pathophysiology of parkinsonism. Understand the pharmacology of drugs.
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
Parkinson’s Disease Dr Rachel Cary, Warwick Hospital.
Pharmacology – II PHL-322 Chapter 4 ANTI-PARKINSONIAN DRUGS
Diagnosis and Treatment of Parkinson’s Disease Jeff Bronstein, MD, PhD Professor of Neurology at UCLA Director of the SW PADRECC Director of UCLA Movement.
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
Initial Diagnosis and Management of Parkinson’s Disease
Harald Bjorndalen Adapted from lecture by Dr Zoe Campbell (Medical SpR)
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
Mosby items and derived items © 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 16 Antiparkinsonian Drugs.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Chapter 30 Agents Used to Treat Parkinson’s Disease.
Objectives Description of Parkinson's disease
By Prof. Hanan Hagar Pharmacology unit Medical College.
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Salvador Dali (Painter) Mao Zedong (Chinese Politician) Michael J Fox (Actor) Pope John Paul II Muhammad Ali (Boxer) Janet Reno (Former AG)
Benjamin L. Walter M.D. Medical Director, Deep Brain Stimulation Program Neurological Institute University Hospitals Case Medical Center Management of.
Represented by SHIVAJI SINGH SAMEER CHAVAN SOURIMA MUKHERJEE SONAL KULKARNI SUVARNA CHAVAN M.Sc (CLINICAL RESEARCH) (CRANFIELD)GROUP-9.
Slide 1 Mosby items and derived items © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 15 Drugs Used for Parkinson’s Disease.
By Prof. Hanan Hagar Pharmacology unit Medical College.
By Katelyn Chaimson and Sean Guyot
Parkinson's disease By Colby Allen. symptoms Mild to major tremors. Rigidity or joint stiffness Bradykinesia or slowness of movement Postural instability.
Drugs in parkinsonism ilos
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. CHAPTER 14 Antiparkinsonian Drugs.
Parkinson’s Disease Angela Duncan June Why I Chose This Subject Common neurodegenerative disorder / in Scotland Expected increase.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
By Seamus Hogan.  Parkinsons disease is degenerative disorder of the central nervous system. it causes the dopamine to contain cells in the substantial.
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
CHAPTER 28 Pharmacologic Management of Parkinsonism and Other Movement Disorders.
Parkinson's disease ♦ Is a neurodegenerative disorder ♦ Develops around age 50 * incidence rises with age * affects 1-2% of population > age 65 ♦ Higher.
PARKINSON’S DISEASE CHAMINDA UNANTENNE RN,MS,MSN.
Drug Therapy for Parkinson’s Disease
“HEALTH IS THE BEST” In the name of God. WHAT IS IT? Parkinson's disease (PD) is a chronic and progressive movement disorder, meaning that symptoms.
PARKINSON’S DISEASE LUKE CARROLL & LAUREN DESROCHES.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Drugs used in Parkinson’s disease
Parkinson's disease.
Drugs Used for Parkinson’s Disease
MOVEMENT DISORDERS ANATOMY The basal ganglia refer to
Parkinsonism.
MOVEMENT DISORDERS.
DRUGS FOR PARKINSONISM
Drugs of Anti-Parkinson’s disease
Drugs for Parkinson’s Disease
Parkinson's disease KRZYSZTOF NICPOŃ.
Dopamine AND PD.
Treatment of Parkinson’s disease
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
Central Nervous System
מחלת פרקינסון מחלת פרקינסון היא מחלה Progressive.
Anti-parkinsonism Drugs
Anti-parkinsonism Drugs
Antiparkinsonian drugs Presented by K.Lakshmi Department of pharmacology Assistant professor SSPC.
Review on Central Nervous System Disorders and Management
Drugs for Degenerative Diseases of the Nervous System
Classification of Epilepsy (p. 227)
Dopaminergic agents Medicinal Chemistry th Year
Pharmacological Management of Parkinson’s Disease
Neurodegenerative diseases
Management in Primary Care
Presentation transcript:

Lecture 3 Dr.Narmin Hussen 15 Dopamine Lecture 3 Dr.Narmin Hussen

Dopamine Some of its notable functions are in: movement memory pleasurable reward behavior and cognition Attention inhibition of prolactin production sleep mood learning

Dopaminergic Pathways

Synthesis of Dopamine precursor of norepinephrine and epinephrine.

Dopamine Receptors DA receptors are divided into five subtypes, D1 to D5

Dopamine Metabolism

Parkinson Disease PD is a progressive neurodegenerative, dopamine deficiency disorder

video-1493659367.mp4

Symptoms of Parkinson's disease Slowness of movement and Shuffling walk Tremor (shaking) Muscle rigidity (Stiffness) Muffled speech

Risk factor Age Genetic factors Head Injury Environmental factors Gender

Diagnosis of Parkinson's disease Clinical features Brain scans(CT or MRI)

Treatment Levodopa:

Levodopa/Carbidopa (sinemet):

MAO-B Inhibitors: 1(R)-aminoindan, 3-hydroxy-N-propargyl-1-aminoindan, and 3-hydroxy-1-aminoindan a selective irreversible inhibitor of MAO-B

Dopamine Agonists DA agonists are classified into: Ergot derivatives (pergolide, cabergoline, and bromocriptine) withdrawn from the market.

Nonergot derivatives (apomorphine, pramipexole, ropinirole, and rotigotine). , 4-carboxymethylindolin-2-one N-despropylrotigotine and N-desthienylethyl rotigotine

COMT Inhibitors: only inhibits peripheral COMT Tolcapone is a selective and reversible inhibitor of COMT in the CNS and periphery Entacapone does not penetrate the BBB